- transplantation, cellular, and immunotherapy childhood acute lymphoblastic leukemia (ALL)
- bone marrow failure syndromes and severe aplastic anemia
- reduced toxicity regimens to decrease toxicity and late effects after transplantation
- donor safety
Dr. Pulsipher’s research Interests are focused in four major areas:
First, he is an international expert in transplantation, cellular, and immunotherapy for children with acute lymphoblastic leukemia. He was PI of a large phase III transplantation trail completed in the Children’s Oncology Group and is currently involved in a second phase III trial. He is a PI and member of the steering committee for anti-CD19 CART cells being developed through Novartis. He has done innovative research in the effect of minimal residual disease and graft vs. host disease after transplantation on outcomes.
His second area of research interest is in bone marrow failure syndromes and severe aplastic anemia. His clinical trials are trying to improve the outcomes of alternative donor transplantation in severe aplastic anemia and moving unrelated donor transplantation to initial therapy in pediatrics.
His third area of research interest is in reduced toxicity regimens, designed to decrease toxicity and late effects after transplantation. He is running a national trial of reduced toxicity approaches in HLH and selected immunodeficiences and also organizing a trial of reduced intensity regimens for children with SCID.
Finally, Dr. Pulsipher has performed extensive research on related donor safety, including the first large, NIH-funded prospective multicenter related donor safety study performed in the US.